Duloxetine hydrochloride + placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Urinary Incontinence, Stress
Conditions
Urinary Incontinence, Stress
Trial Timeline
Oct 1, 2005 → Jan 1, 2007
NCT ID
NCT00244296About Duloxetine hydrochloride + placebo
Duloxetine hydrochloride + placebo is a approved stage product being developed by Eli Lilly for Urinary Incontinence, Stress. The current trial status is completed. This product is registered under clinical trial identifier NCT00244296. Target conditions include Urinary Incontinence, Stress.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00673452 | Approved | Completed |
| NCT00536471 | Approved | Completed |
| NCT00422162 | Approved | Completed |
| NCT00408993 | Phase 3 | Completed |
| NCT00406848 | Approved | Completed |
| NCT00244296 | Approved | Completed |
| NCT00191919 | Phase 3 | Completed |
| NCT00122863 | Phase 3 | Completed |
| NCT00122824 | Phase 3 | Completed |
| NCT00190996 | Phase 3 | Completed |
| NCT00058968 | Phase 3 | Completed |
Competing Products
20 competing products in Urinary Incontinence, Stress